(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use

Size: px
Start display at page:

Download "(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use"

Transcription

1 ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1

2 Austria Austria Bulgaria Bulgaria Czech Republic Czech Republic Roche Austria GmbH, Kytril 3 mg - Engelhorngasse 3, 1211 Wien Injektionslösung Austria Roche Austria GmbH, Engelhorngasse 3, 1211 Wien Austria Roche Bulgaria EOOD, 16 Bialo Pole Str Sofia Bulgaria Roche Bulgaria EOOD, 16 Bialo Pole Str Sofia Bulgaria Roche s.r.o., Dukelských hrdinů Praha 7 Czech Republic Roche s.r.o., Dukelských hrdinů Praha 7 Czech Republic 3 mg/3 ml Solution for Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use Kytril solution injectable Kytril 3 mg/3 ml solution injectable Kytril 1 mg comprimés pelliculés 1 mg Solution for 3 mg Solution for Kytril 1 mg / ml Solution for /infusion Kytril 2 mg 2 mg Film-coated tablet Oral use Kytril inj./inf Solution for /infusion 3 ml 3 mg/3 ml 1 ml (1 mg/ ml) 3 ml (1 mg/ ml) 2

3 Estonia Estonia Roche Eesti OÜ Lõõtsa 2, Tallinn Estonia Roche Eesti OÜ Lõõtsa 2, Tallinn Estonia Roche Oy PL Espoo Roche Oy PL Espoo Roche Oy PL Espoo ROCHE 52 Boulevard du Parc NEUILLY SUR SEINE cedex ROCHE 52 Boulevard du Parc NEUILLY SUR SEINE cedex ROCHE 52 Boulevard du Parc NEUILLY SUR SEINE cedex Kytril 1mg/ml Concentrate for /infusion Kytril 1mg Film-coated tablet Oral use Kytril Kytril Solution for Kytril 3mg/3ml solution injectable pour voie intraveineuse Kytril 1mg/ comprimé pelliculé Kytril 2 mg comprimé pelliculé 3mg/3ml Solution for 2 mg Film-coated tablet Oral use 1mg/ml (1ml and 3ml) 5x1 ml and 5x3 ml 3mg/3ml 3

4 Roche Pharma AG Emil-Barell-Straße Grenzach-Wyhlen Roche Pharma AG Emil-Barell-Straße Grenzach-Wyhlen Roche Pharma AG Emil-Barell-Straße Grenzach-Wyhlen Greece Roche (Hellas ) A.E. Alamanas 4 & Delfon, Maroussi Greece Greece Roche (Hellas ) A.E. Alamanas 4 & Delfon, Maroussi Greece Greece Roche (Hellas ) A.E. Alamanas 4 & Delfon, Maroussi Greece Greece Roche (Hellas ) A.E. Alamanas 4 & Delfon, Maroussi Greece Hungary Roche (Hungary) Ltd H-2040 Budaörs Edison u. 1. Hungary Kevatril 1 mg Solution for Injektionslösung Kevatril Filmtabletten 2 mg 2 mg Film-coated tablet Oral use Kevatril 3 mg Solution for 3 mg/3 ml Injektionslösung Kytril 1mg Film-coated tablet Oral use Kytril 1mg/1ml Solution for Kytril 3mg/3ml Solution for Kytril 1 ml 3 ml 1mg/1ml 3mg/3ml 4

5 Hungary Ireland Ireland Ireland Ireland Roche (Hungary) Ltd H-2040 Budaörs Edison u. 1. Hungary Roche S.p.A. Piazza Durante Milano Roche S.p.A. Piazza Durante Milano Roche S.p.A. Piazza Durante Milano Kytril 3 mg/3 ml Solution for Kytril Tablets 1mg 1mg Film-coated tablet Oral use Kytril Tablets 2mg 2mg Film-coated tablet Oral use Kytril Ampoules concentrate for infusion or Kytril Infusion 3 mg/3 ml concentrate for infusion or 1mg/1ml 3mg/3ml Concentrate for infusion/ Concentrate for infusion/ Kytril 3 mg/3 ml Solution for Kytril Solution for Kytril 3 mg/5 ml Solution for 3 mg/3 ml 1ml contains 1mg granisetron (hydrochloride) 1mg contains 9mg sodium chloride = 3.54 mg sodium 3ml contains 3mg granisetron (hydrochloride) 3ml contains 27mg sodium chloride = mg sodium 3 mg/3 ml 3 mg/5 ml 5

6 Latvia Latvia Luxembourg Luxembourg Roche S.p.A. Piazza Durante Milano Roche S.p.A. Piazza Durante Milano Roche Latvija SIA G. Astras 8b Riga, LV-1082 Latvia Roche Latvija SIA G. Astras 8b Riga, LV-1082 Latvia UAB Roche Lietuva J. Jasinskio 16b, LT Vilnius UAB Roche Lietuva J. Jasinskio 16b, LT Vilnius UAB Roche Lietuva J. Jasinskio 16b, LT Vilnius Kytril Kytril Kytril 1 mg film-coated tablets Solution for Kytril 1mg Film-coated tablet Oral use Kytril 1mg/ml Solution for /infusion Kytril 3mg/3ml Solution for /infusion Kytril solution injectable Kytril 3 mg/3 ml solution injectable 1 mg Solution for 3 mg Solution for 3 mg/3 ml 3 mg/3 ml 6

7 Luxembourg Malta Malta Kytril 1 mg comprimés pelliculés Roche Nederland B.V., Kytril i.v. 3 mg = 3 ml, Postbus 44, 3440 AA Woerden oplossing voor injectie Roche Nederland B.V., Kytril i.v. 1 mg = 1 ml, Postbus 44, 3440 AA Woerden oplossing voor injectie Roche Nederland B.V., Kytril 1 mg tabletten, Postbus 44, 3440 AA Woerden omhulde tabletten Roche Nederland B.V., Kytril 2 mg tabletten, Postbus 44, 3440 AA Woerden omhulde tabletten Roche Farmacêutica Química, Lda Estrada nacional 249-1, , Amadora Roche Farmacêutica Química, Lda Estrada nacional 249-1, , Amadora Kytril Tablets 1mg 1mg Film-coated tablet Oral use Kytril Injection 3mg/3ml 3mg/3ml Concentrate for infusion/ Solution for Solution for 2 mg Film-coated tablet Oral use Kytril 1ml contains 1mg granisetron (hydrochloride) 7

8 Romania Romania Slovak Republic Slovak Republic Slovak Republic Roche Farmacêutica Química, Lda Estrada nacional 249-1, , Amadora Roche Farmacêutica Química, Lda Estrada nacional 249-1, , Amadora Roche Romania SRL 9-9A Dimitrie Pompei Street, Building 19, Entrance B, 3rd Floor, Sector (District) 2, Bucharest Romania Roche Romania SRL 9-9A Dimitrie Pompei Street, Building 19, Entrance B, 3rd Floor, Sector (District) 2, Bucharest Romania Roche Slovensko s.r.o. Cintorínska 3/A Bratislava Slovak Republic Roche Slovensko s.r.o. Cintorínska 3/A Bratislava Slovak Republic F.Hoffmann-La Roche Ltd. Basel, Switzerland Roche farmacevtska družba d.o.o. Vodovodna cesta Ljubljana Kytril Solution for Kytril 3 mg/3 ml Solution for Kytril 1 mg Kytril 3mg/3ml Solution for Kytril 1 mg Kytril 2 mg 2 mg Film-coated tablet Oral use Kytril INJ/INF Concentrate for infusion/ Kytril 2 mg filmsko 2 mg Film-coated tablet Oral use obložene tablete 1 ml () 3 ml (3 mg/3 ml) 3mg/3ml (1mg/ml) 8

9 Roche farmacevtska družba d.o.o. Vodovodna cesta Ljubljana Roche farmacevtska družba d.o.o. Vodovodna cesta Ljubljana Roche Farma S.A. C/ Eucalipto Madrid Roche Farma S.A. C/ Eucalipto Madrid Roche Farma S.A. C/ Eucalipto Madrid Roche AB Box Stockholm Roche AB Box Stockholm Roche AB Box Stockholm Kytril raztopina za injiciranje Kytril 3 mg/3 ml raztopina za injiciranje Kytril 1 mg comprimidos recubiertos con película Kytril solución inyectable Kytril 3 mg/3 ml solución inyectable Solution for 3 mg/3 ml Solution for 1mg/1ml 3mg/3ml Solution for Solution for Kytril Kytril Solution for 5 x 1 ml 5 x 3 ml 9

10 AL7 1TW AL7 1TW AL7 1TW AL7 1TW Kytril Tablets 1mg 1mg Film-coated tablet Oral use Kytril Tablets 2mg 2mg Film-coated tablet Oral use Kytril Ampoule 1mg/1ml 1mg/1ml Concentrate for infusion/ Kytril Infusion 3mg/ml 3mg/3ml Concentrate for infusion/ 1ml contains 1mg granisetron (hydrochloride 1mg of granisetron per 1 ml solution 10

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use

(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of and marketing authorisation holders in the Member s 1 Austria Austria Austria Austria Belgium Belgium Belgium

More information

ANNEX II THE MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR IMPORT AND BATCH RELEASE AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

ANNEX II THE MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR IMPORT AND BATCH RELEASE AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE ANNEX I ANNEX II THE MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR IMPORT AND BATCH RELEASE AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 4 A. MANUFACTURING AUTHORISATION HOLDERS Manufacturers

More information

Annex I. List of nationally authorised medicinal products and marketing authorisation applications

Annex I. List of nationally authorised medicinal products and marketing authorisation applications Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Member State Marketing autorisation Holder Invented Name Strength Pharmaceutical form Route of administration

Member State Marketing autorisation Holder Invented Name Strength Pharmaceutical form Route of administration ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing autorisation Holder

More information

4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection

4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection ANNEX I List of the names, pharmaceutical forms, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Route of ) Austria Bulgaria Cyprus Cyprus Czech Republic

More information

Member State Marketing Authorisation Holder (Invented) Strength Pharmaceutical form Route of administration. Novartis Pharma NV

Member State Marketing Authorisation Holder (Invented) Strength Pharmaceutical form Route of administration. Novartis Pharma NV ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State Marketing Authorisation

More information

Powder for solution for infusion. Powder and solvent for solution for IM injection. Powder and solvent for solution for IV injection

Powder for solution for infusion. Powder and solvent for solution for IM injection. Powder and solvent for solution for IV injection Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, Marketing Authorisation Holders in the Member States 1 Member State EU/EEA Marketing authorisation

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Tamiflu 12 mg/ml powder for oral suspension oseltamivir

PACKAGE LEAFLET: INFORMATION FOR THE USER. Tamiflu 12 mg/ml powder for oral suspension oseltamivir PACKAGE LEAFLET: INFORMATION FOR THE USER Tamiflu 12 mg/ml powder for oral suspension oseltamivir Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Tamiflu 12 mg/ml powder for oral suspension. oseltamivir

PACKAGE LEAFLET: INFORMATION FOR THE USER. Tamiflu 12 mg/ml powder for oral suspension. oseltamivir PACKAGE LEAFLET: INFORMATION FOR THE USER Tamiflu 12 mg/ml powder for oral suspension oseltamivir Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xenical 120mg hard capsules Orlistat

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xenical 120mg hard capsules Orlistat PACKAGE LEAFLET: INFORMATION FOR THE USER Xenical 120mg hard capsules Orlistat Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Tarceva 25 mg film-coated tablets Tarceva 100 mg film-coated tablets Tarceva 150 mg film-coated tablets Erlotinib Read all of this leaflet carefully before you

More information

Annex I. List of nationally authorised medicinal products and marketing authorisation applications

Annex I. List of nationally authorised medicinal products and marketing authorisation applications Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605

More information

Package Leaflet: Information for the user. Perjeta 420 mg concentrate for solution for infusion pertuzumab

Package Leaflet: Information for the user. Perjeta 420 mg concentrate for solution for infusion pertuzumab Package Leaflet: Information for the user Perjeta 420 mg concentrate for solution for infusion pertuzumab Read all of this leaflet carefully before you start being given this medicine because it contains

More information

(Invented) Name Strength Pharmaceutical form

(Invented) Name Strength Pharmaceutical form ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Austria Austria Austria

More information

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Levonorgestrel-containing emergency contraceptive medicinal

More information

Package leaflet: Information for the user Esbriet 267 mg hard capsules Pirfenidone

Package leaflet: Information for the user Esbriet 267 mg hard capsules Pirfenidone Appendix 1 Package leaflet: Information for the user Esbriet 267 mg hard capsules Pirfenidone This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xenical 120mg hard capsules Orlistat

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xenical 120mg hard capsules Orlistat PACKAGE LEAFLET: INFORMATION FOR THE USER Xenical 120mg hard capsules Orlistat Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again.

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

1. What MabThera is and what it is used for

1. What MabThera is and what it is used for Package leaflet: Information for the patient MabThera 1400 mg solution for subcutaneous injection rituximab Read all of this leaflet carefully before you are given this medicine because it contains important

More information

Package leaflet: Information for the patient. Cotellic 20 mg film-coated tablets cobimetinib

Package leaflet: Information for the patient. Cotellic 20 mg film-coated tablets cobimetinib Package leaflet: Information for the patient Cotellic 20 mg film-coated tablets cobimetinib This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

More information

Sortis 10 mg - Filmtabletten. Sortis 20 mg - Filmtabletten. Sortis 40 mg - Filmtabletten. Sortis 80 mg - Filmtabletten

Sortis 10 mg - Filmtabletten. Sortis 20 mg - Filmtabletten. Sortis 40 mg - Filmtabletten. Sortis 80 mg - Filmtabletten Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States 1 Member State EU/EEA Austria Austria

More information

BONVIVA 150 mg film-coated tablets

BONVIVA 150 mg film-coated tablets PACKAGE LEAFLET: INFORMATION FOR THE USER BONVIVA 150 mg film-coated tablets IBANDRONIC ACID This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Marketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration Novartis Pharma GmbH

Marketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration Novartis Pharma GmbH ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State EU/EEA Austria Austria Austria

More information

Tadim 1 Million I.E. Pulver zur Herstellung einer Infusionslösung. Tadim 1 Million I.E. Pulver zur Herstellung einer Lösung für einen Vernebler

Tadim 1 Million I.E. Pulver zur Herstellung einer Infusionslösung. Tadim 1 Million I.E. Pulver zur Herstellung einer Lösung für einen Vernebler Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration and marketing authorisation s in the member states 1 Austria Forest Pharma B.V. Newtonlaan

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill

More information

Package leaflet: Information for the patient. Tecentriq 1,200 mg concentrate for solution for infusion atezolizumab

Package leaflet: Information for the patient. Tecentriq 1,200 mg concentrate for solution for infusion atezolizumab Package leaflet: Information for the patient Tecentriq 1,200 mg concentrate for solution for infusion atezolizumab This medicine is subject to additional monitoring. This will allow quick identification

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xenical 120mg hard capsules Orlistat

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xenical 120mg hard capsules Orlistat PACKAGE LEAFLET: INFORMATION FOR THE USER Xenical 120mg hard capsules Orlistat Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xenical 120mg hard capsules Orlistat

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xenical 120mg hard capsules Orlistat PACKAGE LEAFLET: INFORMATION FOR THE USER Xenical 120mg hard capsules Orlistat Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

More information

Package leaflet: Information for the patient. Ocrevus 300 mg concentrate for solution for infusion Ocrelizumab

Package leaflet: Information for the patient. Ocrevus 300 mg concentrate for solution for infusion Ocrelizumab Package leaflet: Information for the patient Ocrevus 300 mg concentrate for solution for infusion Ocrelizumab This medicine is subject to additional monitoring. This will allow quick identification of

More information

(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten

(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Bulgaria Bulgaria Czech Republic Kwizda Pharma

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Herceptin 600 mg solution for injection in vial Trastuzumab

PACKAGE LEAFLET: INFORMATION FOR THE USER. Herceptin 600 mg solution for injection in vial Trastuzumab PACKAGE LEAFLET: INFORMATION FOR THE USER Herceptin 600 mg solution for injection in vial Trastuzumab Read all of this leaflet carefully before you start using this medicine because it contains important

More information

Package Leaflet: Information for the user. Tamiflu 6 mg/ml powder for oral suspension oseltamivir

Package Leaflet: Information for the user. Tamiflu 6 mg/ml powder for oral suspension oseltamivir Package Leaflet: Information for the user Tamiflu 6 mg/ml powder for oral suspension oseltamivir Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Package leaflet: Information for the user. Hemlibra 150 mg/ml solution for injection. emicizumab

Package leaflet: Information for the user. Hemlibra 150 mg/ml solution for injection. emicizumab Package leaflet: Information for the user Hemlibra 150 mg/ml solution for injection emicizumab This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

More information

Package Leaflet: Information for the user. Tamiflu 6 mg/ml powder for oral suspension oseltamivir

Package Leaflet: Information for the user. Tamiflu 6 mg/ml powder for oral suspension oseltamivir Package Leaflet: Information for the user Tamiflu 6 mg/ml powder for oral suspension oseltamivir Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

B. PACKAGE LEAFLET 25

B. PACKAGE LEAFLET 25 B. PACKAGE LEAFLET 25 PACKAGE LEAFLET: INFORMATION FOR THE USER PROTELOS 2 g granules for oral suspension Strontium ranelate Read all of this leaflet carefully before you start taking this medicine. -

More information

Package leaflet: Information for the user. Zelboraf 240 mg film-coated tablets vemurafenib

Package leaflet: Information for the user. Zelboraf 240 mg film-coated tablets vemurafenib Package leaflet: Information for the user Zelboraf 240 mg film-coated tablets vemurafenib Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Invented name Strength. 125mg/5ml. 250mg/5ml

Invented name Strength. 125mg/5ml. 250mg/5ml Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States Member State (EU/EEA) Marketing Authorisation

More information

Package leaflet: Information for the patient. Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride

Package leaflet: Information for the patient. Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride Package leaflet: Information for the patient Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because

More information

Package leaflet: Information for the user. Xeloda 150 mg film-coated tablets Xeloda 500 mg film-coated tablets capecitabine

Package leaflet: Information for the user. Xeloda 150 mg film-coated tablets Xeloda 500 mg film-coated tablets capecitabine Package leaflet: Information for the user Xeloda 150 mg film-coated tablets Xeloda 500 mg film-coated tablets capecitabine Read all of this leaflet carefully before you start taking this medicine because

More information

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing Authorisation

More information

(Invented) Name Strength Pharmaceutical form. Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml. 2.5 mg prolonged-release capsule, hard

(Invented) Name Strength Pharmaceutical form. Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml. 2.5 mg prolonged-release capsule, hard Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Boehringer Ingelheim RCV GmbH & Co KG, Dr.

More information

Package leaflet: Information for the patient. MabThera 100 mg concentrate for solution for infusion rituximab

Package leaflet: Information for the patient. MabThera 100 mg concentrate for solution for infusion rituximab Package leaflet: Information for the patient MabThera 100 mg concentrate for solution for infusion rituximab Read this leaflet carefully before you start taking this medicine because it contains important

More information

Package leaflet: Information for the user. Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa

Package leaflet: Information for the user. Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa Package leaflet: Information for the user Myozyme 50 mg powder for concentrate for solution for infusion Alglucosidase alfa Read all of this leaflet carefully before you start using this medicine because

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill

More information

Package leaflet: Information for the patient. Xydalba 500 mg powder for concentrate for solution for infusion dalbavancin

Package leaflet: Information for the patient. Xydalba 500 mg powder for concentrate for solution for infusion dalbavancin Package leaflet: Information for the patient Xydalba 500 mg powder for concentrate for solution for infusion dalbavancin This medicine is subject to additional monitoring. This will allow quick identification

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Herceptin 150 mg powder for concentrate for solution for infusion Trastuzumab

PACKAGE LEAFLET: INFORMATION FOR THE USER. Herceptin 150 mg powder for concentrate for solution for infusion Trastuzumab PACKAGE LEAFLET: INFORMATION FOR THE USER Herceptin 150 mg powder for concentrate for solution for infusion Trastuzumab Read all of this leaflet carefully before you start using this medicine because it

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus L4 suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml

More information

Package leaflet: Information for the patient. Fuzeon 90 mg/ml powder and solvent for solution for injection Enfuvirtide

Package leaflet: Information for the patient. Fuzeon 90 mg/ml powder and solvent for solution for injection Enfuvirtide Package leaflet: Information for the patient Fuzeon 90 mg/ml powder and solvent for solution for injection Enfuvirtide Read all of this leaflet carefully before you start using this medicine because it

More information

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES 1 Member State EU/EEA Marketing Authorisation Holder Austria

More information

Package leaflet: Information for the user. Sevelamer carbonate Zentiva 800 mg film-coated tablets sevelamer carbonate

Package leaflet: Information for the user. Sevelamer carbonate Zentiva 800 mg film-coated tablets sevelamer carbonate Package leaflet: Information for the user Sevelamer carbonate Zentiva 800 mg film-coated tablets sevelamer carbonate Read all of this leaflet carefully before you start taking this medicine because it

More information

Package leaflet: Information for the user. Renvela 800 mg film-coated tablets sevelamer carbonate

Package leaflet: Information for the user. Renvela 800 mg film-coated tablets sevelamer carbonate Package leaflet: Information for the user Renvela 800 mg film-coated tablets sevelamer carbonate Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Package leaflet: Information for the user CellCept 1 g/5 ml powder for oral suspension (mycophenolate mofetil)

Package leaflet: Information for the user CellCept 1 g/5 ml powder for oral suspension (mycophenolate mofetil) Package leaflet: Information for the user CellCept 1 g/5 ml powder for oral suspension (mycophenolate mofetil) Read all of this leaflet carefully before you start taking this medicine because it contains

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

Package leaflet: Information for the patient. Gazyvaro 1,000 mg concentrate for solution for infusion Obinutuzumab

Package leaflet: Information for the patient. Gazyvaro 1,000 mg concentrate for solution for infusion Obinutuzumab Package leaflet: Information for the patient Gazyvaro 1,000 mg concentrate for solution for Obinutuzumab This medicine is subject to additional monitoring. This will allow quick identification of new safety

More information

Package leaflet: Information for the patient. Zeffix 100 mg film-coated tablets lamivudine

Package leaflet: Information for the patient. Zeffix 100 mg film-coated tablets lamivudine Package leaflet: Information for the patient Zeffix 100 mg film-coated tablets lamivudine Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to

More information

1. What RoActemra is and what it is used for

1. What RoActemra is and what it is used for Package leaflet: Information for the user RoActemra 162 mg solution for injection in pre-filled pen (ACTPen ) Tocilizumab Read all of this leaflet carefully before you start using this medicine because

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Package leaflet: Information for the patient. Integrilin 2 mg/ml solution for injection eptifibatide

Package leaflet: Information for the patient. Integrilin 2 mg/ml solution for injection eptifibatide Package leaflet: Information for the patient Integrilin 2 mg/ml solution for injection eptifibatide Read all of this leaflet carefully before you start using this medicine because it contains important

More information

Package leaflet: Information for the patient. Tadalafil Mylan 2.5 mg film-coated tablets Tadalafil

Package leaflet: Information for the patient. Tadalafil Mylan 2.5 mg film-coated tablets Tadalafil Package leaflet: Information for the patient Tadalafil Mylan 2.5 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

Package leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride

Package leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Package leaflet: Information for the user Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using this medicine because

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER NALOXONE 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using

More information

INN Product name Strength Pharmaceutical form

INN Product name Strength Pharmaceutical form Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation (s) in the member states 1 Targin 10 mg/5 mg prolongedrelease Targin 20 mg/10

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Metfmin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metfmin hydrochlide Read all of this leaflet carefully befe you start taking this medicine.

More information

Orlistat EG 60 mg capsule, hard oral use. Orlistat EG 120 mg capsule, hard oral use. Orlistat Sandoz 60 mg capsule, hard oral use

Orlistat EG 60 mg capsule, hard oral use. Orlistat EG 120 mg capsule, hard oral use. Orlistat Sandoz 60 mg capsule, hard oral use ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATIONS AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Belgium Belgium Belgium Belgium

More information

Product name Strength Pharmaceutical form. Flupirtinmaleat AbZ 100 mg Kapseln. Flupirtinmaleat AL 100 mg Hartkapseln. Awegal inject 164,5 mg / 3 ml

Product name Strength Pharmaceutical form. Flupirtinmaleat AbZ 100 mg Kapseln. Flupirtinmaleat AL 100 mg Hartkapseln. Awegal inject 164,5 mg / 3 ml Annex I List of the names, pharmaceutical s, strengths of the medicinal products, route of, marketing authorisation s in the Member States 1 Bulgaria Estonia Zentiva k.s. 130 U kabelovn Prague 10237 Czech

More information

1. What RoActemra is and what it is used for

1. What RoActemra is and what it is used for Package leaflet: Information for the user RoActemra 162 mg solution for injection in pre-filled syringe Tocilizumab Read all of this leaflet carefully before you start using this medicine because it contains

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equip WNV emulsion for injection for horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:

More information

Package leaflet: Information for the user. Fluenz Tetra nasal spray suspension Influenza vaccine (live attenuated, nasal)

Package leaflet: Information for the user. Fluenz Tetra nasal spray suspension Influenza vaccine (live attenuated, nasal) Package leaflet: Information for the user Fluenz Tetra nasal spray suspension Influenza vaccine (live attenuated, nasal) This medicine is subject to additional monitoring. This will allow quick identification

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user MIRCERA 30 micrograms/0.3 ml solution for injection in pre-filled syringe 40 micrograms/0.3 ml solution for injection in pre-filled syringe 50 micrograms/0.3 ml

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. AZILECT 1 mg tablets Rasagiline

PACKAGE LEAFLET: INFORMATION FOR THE USER. AZILECT 1 mg tablets Rasagiline PACKAGE LEAFLET: INFORMATION FOR THE USER AZILECT 1 mg tablets Rasagiline Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again. -

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Package leaflet: Information for the patient Vipidia 25 mg film-coated tablets Vipidia 12.5 mg film-coated tablets Vipidia 6.25 mg film-coated tablets alogliptin Read all of this leaflet carefully before

More information

PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER. chloroprocaine hydrochloride

PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER. chloroprocaine hydrochloride Page 1 PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER Ampres 10 mg/ml solution for injection chloroprocaine hydrochloride Read all of this leaflet carefully before you are given this medicine

More information

B. PACKAGE LEAFLET 21

B. PACKAGE LEAFLET 21 B. PACKAGE LEAFLET 21 PACKAGE LEAFLET: INFORMATION FOR THE USER Defitelio 80 mg/ml concentrate for solution for infusion Defibrotide This medicine is subject to additional monitoring. This will allow quick

More information

leflunomide Package leaflet: Information for the user Leflunomide Winthrop 20 mg film-coated tablets

leflunomide Package leaflet: Information for the user Leflunomide Winthrop 20 mg film-coated tablets Package leaflet: Information for the user Leflunomide Winthrop 20 mg film-coated tablets leflunomide Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Levonorgestrel-containing emergency contraceptive medicinal

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Savene 20 mg/ml powder for concentrate and diluent for solution for infusion.

PACKAGE LEAFLET: INFORMATION FOR THE USER. Savene 20 mg/ml powder for concentrate and diluent for solution for infusion. PACKAGE LEAFLET: INFORMATION FOR THE USER Savene 20 mg/ml powder for concentrate and diluent for solution for infusion (dexrazoxane) Read all of this leaflet carefully before you start using this medicine

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. CIALIS 10 mg film-coated tablets tadalafil

PACKAGE LEAFLET: INFORMATION FOR THE USER. CIALIS 10 mg film-coated tablets tadalafil PACKAGE LEAFLET: INFORMATION FOR THE USER CIALIS 10 mg film-coated tablets tadalafil Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read

More information

Cosaar 12,5 mg - Filmtabletten. Cosaar 50 mg - Filmtabletten. Cosaar 100 mg - Filmtabletten COZAAR CARDIO START. 21 X 12,5 mg + 14 X 50 mg

Cosaar 12,5 mg - Filmtabletten. Cosaar 50 mg - Filmtabletten. Cosaar 100 mg - Filmtabletten COZAAR CARDIO START. 21 X 12,5 mg + 14 X 50 mg ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM(S), STRENGTH(S), ROUTE(S) OF ADMINISTRATION OF THE MEDICINAL PRODUCT(S), MARKETING AUTHORISATION HOLDER(S) IN THE MEMBER STATES Member State Marketing Authorisation

More information

Package leaflet: Information for the user. Hemlibra 30 mg/ml solution for injection. emicizumab

Package leaflet: Information for the user. Hemlibra 30 mg/ml solution for injection. emicizumab Package leaflet: Information for the user Hemlibra 30 mg/ml solution for injection emicizumab This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

More information

PACKAGE LEAFLET For medicinal products available on prescription

PACKAGE LEAFLET For medicinal products available on prescription PACKAGE LEAFLET PACKAGE LEAFLET For medicinal products available on prescription Package leaflet: Information for the user Zirtek 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet

More information

Package leaflet: Information for the user. Clopidogrel Mylan 75 mg film-coated tablets clopidogrel

Package leaflet: Information for the user. Clopidogrel Mylan 75 mg film-coated tablets clopidogrel Package leaflet: Information for the user Clopidogrel Mylan 75 mg film-coated tablets clopidogrel Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin

PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Annex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection

Annex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection 07 March 2013 EMA/147828/2013 Patient Health Protection Annex I List of the names, pharmaceutical s, strengths of the medicinal products, routes of, marketing authorisation holders in the member states

More information

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you. Package leaflet: Information for the patient Byetta 5 micrograms solution for injection in pre-filled pen Byetta 10 micrograms solution for injection in pre-filled pen exenatide Read all of this leaflet

More information

Package leaflet: Information for the user. Rhesonativ 625 IU/ml, solution for injection Human anti-d immunoglobulin

Package leaflet: Information for the user. Rhesonativ 625 IU/ml, solution for injection Human anti-d immunoglobulin Package leaflet: Information for the user Human anti-d immunoglobulin Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this

More information

Package leaflet: Information for the user. Benlysta 120 mg powder for concentrate for solution for infusion

Package leaflet: Information for the user. Benlysta 120 mg powder for concentrate for solution for infusion Package leaflet: Information for the user Benlysta 120 mg powder for concentrate for solution for infusion Benlysta 400 mg powder for concentrate for solution for infusion Belimumab This medicine is subject

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Package leaflet: Information for the patient Oprymea 0.088 mg tablets Oprymea 0.18 mg tablets Oprymea 0.35 mg tablets Oprymea 0.7 mg tablets Oprymea 1.1 mg tablets Pramipexole Read all of this leaflet

More information

Smokefree Policies in Europe: Are we there yet?

Smokefree Policies in Europe: Are we there yet? Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially

More information